Of interest, in the setting of metabolic syndromes, the majority of available studies have investigated the effects of NLRP3-targeting phytochemicals in complications associated with obesity and diabetes, including hepatic inflammation, non-alcoholic fatty liver disease (NAFLD), diabetic nephropathy, and cognitive impairment [29,39,40,41,42,43]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.